Jalowiec A, Grady K L, White-Williams C, Fazekas S, Laff M, Davidson-Bell V, Kracht E, Willson W
Niehoff School of Nursing, Loyola University Medical Center, Maywood, IL 60153, USA.
J Heart Lung Transplant. 1997 Jun;16(6):604-14.
Although symptoms of heart failure abate after heart transplantation, other symptoms caused by the surgery, immunosuppressant drugs, and complications can be new sources of symptom distress for patients after operation.
This two-site National Institutes of Health study compared symptom distress in 173 adult heart transplant recipients from before operation to 3 months after operation. The Heart Transplant Symptom Scale was used to measure 92 symptoms related to heart disease and heart failure, transplantation, medication side effects, and complications commonly found in this population. Analysis was via paired t tests with Bonferroni correction. Most patients (93%) were receiving a triple immunosuppressant regimen of cyclosporine, azathioprine, and prednisone.
Total symptom distress decreased significantly (p = 0.013) from before operation to 3 months after heart transplantation. The 23 symptoms that decreased the most (p = 0.000) after operation accounted for a cumulative total reduction of 583% less symptom distress. These symptoms were primarily cardiopulmonary, neuromuscular, and emotional. The 10 symptoms that worsened the most (p = 0.000) after operation accounted for a cumulative total increase of 284% more symptom distress. These symptoms were primarily dermatologic, neurologic, and gastrointestinal and were all side effects of prednisone and cyclosporine.
The net change in symptom distress resulted in 299% less symptom distress in this cohort at 3 months after heart transplantation. This significant improvement in symptom outcomes scientifically documents the effectiveness of heart transplantation in reducing symptoms of heart failure, along with accompanying emotional symptoms. These research findings therefore reinforce and support the positive symptom outcomes often reported anecdotally in clinical practice.
尽管心脏移植后心力衰竭症状会减轻,但手术、免疫抑制药物及并发症所引发的其他症状可能成为患者术后症状困扰的新来源。
这项由美国国立卫生研究院开展的双中心研究对173名成年心脏移植受者术前至术后3个月的症状困扰情况进行了比较。采用心脏移植症状量表来测量与该人群常见的心脏病、心力衰竭、移植、药物副作用及并发症相关的92种症状。分析采用经Bonferroni校正的配对t检验。大多数患者(93%)接受环孢素、硫唑嘌呤和泼尼松的三联免疫抑制方案。
从术前到心脏移植术后3个月,总症状困扰显著降低(p = 0.013)。术后下降最为明显(p = 0.000)的23种症状,其症状困扰累计减少了583%。这些症状主要是心肺、神经肌肉和情绪方面的。术后恶化最为明显(p = 0.000)的10种症状,其症状困扰累计增加了284%。这些症状主要是皮肤、神经和胃肠道方面的,均为泼尼松和环孢素的副作用。
在心脏移植术后3个月,该队列中症状困扰的净变化使症状困扰减少了299%。症状结果的这一显著改善科学地证明了心脏移植在减轻心力衰竭症状及伴随的情绪症状方面的有效性。因此,这些研究结果强化并支持了临床实践中经常轶事报道的积极症状结果。